Reuters: Global Markets: Drugmaker GSK raises bet on Response Genetics

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Drugmaker GSK raises bet on Response Genetics Sep 13th 2012, 20:29 LONDON | Thu Sep 13, 2012 4:29pm EDT LONDON (Reuters) - GlaxoSmithKline (GSK.L) has bought 5 million newly issued shares in diagnostics firm Response Genetics (RGDX.O) for $1.10 each, giving it a stake of 15.2 percent and sending shares in the U.S. company sharply higher. The investment follows a deal between the two firms in 2010 that gave British-based GSK rights to Response's gene mutation testing technology, an area of growing importance to drugmakers as they target treatments according to patients' genetic profiles. GSK said Response was performing companion diagnostic tests and other related activities for its immunotherapies and oncology pipeline candidates. Shares in Response jumped 21 percent to $1.09 each in pre-market Nasdaq trading on Thursday.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions